B J Rembacken

Summary

Country: UK

Publications

  1. ncbi Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial
    B J Rembacken
    Centre for Digestive Diseases, The General Infirmary at Leeds, UK
    Lancet 354:635-9. 1999

Detail Information

Publications1

  1. ncbi Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial
    B J Rembacken
    Centre for Digestive Diseases, The General Infirmary at Leeds, UK
    Lancet 354:635-9. 1999
    ..coli (Nissle 1917) was as effective as mesalazine in preventing relapse of ulcerative colitis. We also examined whether the addition of E. coli to standard medical therapy increased the chance of remission of active ulcerative colitis...